July 2019
Finish Cancer Through Research
Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.
Can adjuvant immunotherapy prevent recurrence of
high-risk cutaneous squamous cell carcinoma?
Photo Credit: National Cancer Institute
A new phase 3 study open at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute, will evaluate the curative potential of adjuvant pembrolizumab in patients with high-risk or locally-advanced cutaneous squamous cell carcinoma. Pembrolizumab (Keytruda) is a checkpoint inhibitor approved as frontline treatment for several types of cancer.
All current open studies:
Find additional studies for many types of cancer in Multiple Tumor Types .
New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.